Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

Dasatinib in the Second-Line CML Setting

Panelists: Jessica K. Altman, MD, Northwestern University; Stuart L. Goldberg, MD, Rutgers;Elias Jabbour, MD, MD Anderson; Neil P. Shah, MD, PhD; UC
Published: Saturday, Mar 07, 2015
For High-Definition, Click
Dasatinib is structurally distinct from both imatinib and nilotinib, which suggests that it could still be effective in patients with chronic myelogenous leukemia (CML) who experience resistance to these therapies, explains Neil P. Shah, MD, PhD. However, one constraint may be the existence of cross-resistant mutations, such as F317 and the T315I.

In the phase III CA180-034 study, patients with chronic phase CML who were resistant to prior treatment with imatinib received second-line dasatinib. At a median 5-year analysis, 64% of patients were alive, 14% had an unknown status, and 22% had passed away. The major cytogenetic response at 2-years was 63% with dasatinib.

While long-term data show overall safety, there are a limited number of patients that experience pulmonary arterial hypertension and pleural effusion, Shah suggests. Still, patients appreciate the convenience of it being a once-a-day pill that can be taken with or without food.
Slider Left
Slider Right
For High-Definition, Click
Dasatinib is structurally distinct from both imatinib and nilotinib, which suggests that it could still be effective in patients with chronic myelogenous leukemia (CML) who experience resistance to these therapies, explains Neil P. Shah, MD, PhD. However, one constraint may be the existence of cross-resistant mutations, such as F317 and the T315I.

In the phase III CA180-034 study, patients with chronic phase CML who were resistant to prior treatment with imatinib received second-line dasatinib. At a median 5-year analysis, 64% of patients were alive, 14% had an unknown status, and 22% had passed away. The major cytogenetic response at 2-years was 63% with dasatinib.

While long-term data show overall safety, there are a limited number of patients that experience pulmonary arterial hypertension and pleural effusion, Shah suggests. Still, patients appreciate the convenience of it being a once-a-day pill that can be taken with or without food.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x